Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors - An assessment of the efficacy of testing in donor screening

Abstract Background. We performed a multicenter study in 1989 to determine whether screening whole-blood donors for human immunodeficiency virus type 1 (HIV-1) p24 antigen would improve transfusion safety by identifying carriers of the virus who are seronegative for HIV-1 antibody. Methods. More than 500,000 donations were tested at 13 U.S. blood centers with test kits from two manufacturers. Units found repeatedly reactive were retested in a central laboratory; if the results were positive, they were confirmed by a neutralization assay. A subgroup of units was also tested for HIV-1 by the polymerase chain reaction. Selected donors confirmed or not confirmed as having p24 antigen were contacted for follow-up interviews to identify risk factors and undergo retesting for HIV-1 markers. Results. Positive tests for p24 antigen were confirmed by neutralization in five donors (0.001 percent of all donations tested), all of whom were also positive for HIV-1 antibody and HIV-1 by polymerase chain reaction. Three ...

[1]  J. Albert,et al.  HIV ANTIGENAEMIA AND VIRUS ISOLATION FROM PLASMA DURING PRIMARY HIV INFECTION , 1987, The Lancet.

[2]  Sandler Sg,et al.  A model for estimating incremental benefits and costs of testing donated blood for human immunodeficiency virus antigen (HIV-Ag). , 1990 .

[3]  A. Fauci,et al.  Stages in the progression of HIV infection in chimpanzees. , 1987, AIDS research and human retroviruses.

[4]  I. Hewlett,et al.  Co-amplification of multiple regions of the HIV-1 genome by the polymerase chain reaction: potential use in multiple diagnosis. , 1989, Oncogene.

[5]  B. Polk,et al.  Transmission of Retroviruses by Transfusion of Screened Blood in Patients Undergoing Cardiac Surgery , 1989, The New England journal of medicine.

[6]  Y. Laurian,et al.  SEROLOGICAL MARKERS IN EARLY STAGES OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HAEMOPHILIACS , 1986, The Lancet.

[7]  J. Ward,et al.  DURATION OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION BEFORE DETECTION OF ANTIBODY , 1989, The Lancet.

[8]  J. Ocaríz,et al.  Optimal volume of plasma exchange in thrombotic thrombocytopenic purpura , 1987, Transfusion.

[9]  P D Cumming,et al.  Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. , 1989, The New England journal of medicine.

[10]  S. Kleinman,et al.  Risk of human immunodeficiency virus (HIV) transmission by anti‐HIV negative blood , 1988, Transfusion.

[11]  Henry A. Erlich,et al.  Analysis of enzymatically amplified β-globin and HLA-DQα DNA with allele-specific oligonucleotide probes , 1986, Nature.

[12]  P. Feorino,et al.  Comparison of antigen assay and reverse transcriptase assay for detecting human immunodeficiency virus in culture , 1987, Journal of clinical microbiology.

[13]  K. Lui,et al.  Estimating the risks of transfusion‐associated acquired immune deficiency syndrome and human immunodeficiency virus infection , 1987, Transfusion.

[14]  L. Epstein,et al.  EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN (HIV-Ag) IN SERUM AND CEREBROSPINAL FLUID DURING ACUTE AND CHRONIC INFECTION , 1986, The Lancet.

[15]  H. Klein,et al.  Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. , 1989, The New England journal of medicine.

[16]  J. Ward,et al.  Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. , 1988, The New England journal of medicine.

[17]  J. Eberle,et al.  HIV ANTIGEN SCREENING IN BLOOD DONORS , 1987, The Lancet.

[18]  J. Ward,et al.  Epidemiologic characteristics of blood donors with antibody to human immunodeficiency virus , 1988, Transfusion.